Switzerland wants lower drug prices
Switzerland is looking to put the squeeze on drugmakers, or at least that's the industry's perspective on things. Reuters reports that the home country of manufacturers Roche and Novartis is pushing for lower pharmaceutical prices, such as a 30% discount for Roche's breast cancer treatment Perjeta (pertuzumab). The company refused and Roche chairman Christoph Franz said in an interview with Basier Zeitung that accepting such a cut could expose the company to a similar pricing fight beyond Switzerland's borders.
Reuters notes that Switzerland accounts for only around 1% or 2% of pharmaceutical sales and that its citizens spend about half of what Americans do, and less than neighbors such as Belgium, Germany and Ireland.